By combining the results of multivariable adjusted data, our study showed that MetS was associated with higher overall mortality (P=0.004) and recurrence risk (P=0.007) in BC patients who received NAC, and this association was independent of some known prognostic factors, such as age, disease stage, and hormone receptors status. The gene discussed is NR4A1; the disease is metabolic syndrome.